
Kyverna Therapeutics' IPO Surge and Cell Therapy Plans
Kyverna Therapeutics saw its shares surge over 50% on its first day as a public biotech company after pricing at $22 and raising $319 million, following five years of development and private fundraising. CEO Peter Maag outlined plans for cell therapy in immune diseases, emphasizing the company's long journey and the support of its "Kyverna village."
